Covagen Company
Covagen is a company that develops bispecific FynomAbs, which are therapeutics created by fusing human Fynomer binding proteins to antibodies. They aim to create tailored architectures to maximize efficacy and access novel biology for each product candidate. Their lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases. Covagen was founded in 2007 as a spin-off company from ETH Zurich and has a strong syndicate of investors supporting their drug development programs. They entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL in October 2012 for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL.
Investors
%20.jpg)
Founded Date:
2007
Total Funding:
$10.6M
Employee Number:
11-50
Funding Status:
M&A
Technology:
Data-driven Technologies
Last Funding Type:
Venture - Series Unknown
Industry:
Geroscience
Headquarters:
Schlieren, Zurich
Estimated Revenue:
$10M to $50M